PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37087376.
- Also identified by DOI 10.1016/j.eururo.2023.03.038.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The combination of PARP and androgen receptor signalling inhibitors is best reserved for cases for which we expect an overall survival benefit on the basis of disease biology. The data to date should encourage us to perform more, not less, testing for DNA repair defects.
Medical subject headings
- Poly(ADP-ribose) Polymerase Inhibitors
- Prostatic Neoplasms, Castration-Resistant